Medical - Instruments & Supplies · NYSE
当前价格
$220.47
内在价值
使用下方计算器估算
对 ResMed Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Earnings Yield
4.60%
ROE (TTM)
24.8%
基于过去 12 个月的数据，RMD 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
RMD 的过去 12 个月市盈率反映投资者为 ResMed Inc. 每一美元收益所支付的价格。该指标在与Medical - Instruments & Supplies同类公司和公司自身历史区间对比时最有意义。
RMD 是否被高估取决于将其市盈率与Medical - Instruments & Supplies同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估，但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 ResMed Inc. 使用 PE 估值的步骤：(1) 将当前市盈率与Medical - Instruments & Supplies中位数对比评估相对定价，(2) 查看 PEG 比率以调整增长预期，(3) 参考 5 年 PE 历史区间判断当前位置，(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速，提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估，高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——RMD 相对于Medical - Instruments & Supplies同类的估值水平。DCF 基于预期自由现金流提供绝对价值。对于 RMD，ROE 达到 24.8%，两种方法都值得使用——PE 做市场对比，DCF 验证基本面是否支撑当前价格。两种方法各有盲区：PE 忽略了资本结构和现金流质量，DCF 则对增长率和折现率假设非常敏感。
